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A B S T R A C T
A concomitant condition found in many patients with atrial fibrillation (AF) com-
monly requires bradycardia pacing. Comparing AAI to VVI pacing, atrial pacing ap-
pears to have an apparent protective effect on the subsequent development of AF. By 
addressing the proposed mechanisms responsible for AF (long-short cycles, increased 
temporal dispersion of refractoriness, frequent atrial ectopic beats), overdrive appears 
to be a promising technique to postpone or even prevent entirely the development of 
chronic AF while reducing the incidence of paroxysmal AF. These observations led to 
the development of a pacing algorithm (Dynamic Atrial Overdrive-DAO) designed to 
provide a high percentage of atrial pacing just above the patient’s own intrinsic atrial 
rate. The algorithm is a dynamic stimulation technique to suppress AF effectively, 
overdrives the atrium just enough to prevent the intrinsic rhythm from emerging while 
maintaining both normal diurnal variation and rate response.
Dynamic Atrial Overdrive is a unique pacemaker algorithm designed specifically for 
suppression of paroxysmal AF arising from either an absolute or relative bradycardia. 
By maintaining an atrial stimulation rate just above the intrinsic rate, the goal is to 
control both the atrial rate and rhythm, reducing the incidence of ectopic beats which 
might be a trigger, long-short cycles, or the dispersion of refractoriness from initiating 
AF. In addition, because the algorithm routinely searches for intrinsic atrial activity 
and adjusts the stimulation rate accordingly, it avoids sustained periods of rapid stim-
ulation that may not be required. At the same time, it preserves the normal circadian 
rate variation in association with normal sinus function or in the presence of sinus 
node dysfunction if the sleep rate feature is also enabled.
I N T R O D U C T I O N
Atrial fibrillation (AF), the most common significant cardiac arrhythmia, affects an 
estimated 4 million people around the world. Its rapid and uncoordinated atrial rhythm 
compromises hemodynamics, decreases cardiac output, predisposes to ventricular ar-
rhythmias, and sets the stage for thromboembolic complications. Contributing mecha-
nisms are presumed to be the occurrence of long-short cycles, an increased temporal 
dispersion of refractoriness, and atrial ectopic activity. The incidence increases with 
age, affecting 4% of those over 60, and up to 15% of those over 70.1,2 Although it can 
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occur in the absence of concomitant structural heart disease 
(“lone” AF), it is most often associated with a number of 
complicating conditions including hypertension, organic heart 
disease, coronary artery disease and others.
While the natural history of AF has not been conclusively 
established, it appears to start with brief paroxysmal episodes 
that are self-terminating. The next stage is persistent charac-
terized by more prolonged episodes that require intervention 
to terminate. Finally a chronic stage develops where attempts 
to terminate the rhythm and restore normal sinus rhythm are 
essentially abandoned in favor of controlling the resulting 
ventricular rate and managing other consequences.3
The health care costs associated with this arrhythmia are 
enormous. It has been reported to account for one-third of 
hospital days for all patient discharges where arrhythmia was 
the primary diagnosis,4 with an estimated cost of over $1 bil-
lion annually in the United States alone.
Historically, because of the absence of truly curative 
interventions and the risks and costs associated with re-
peated cardioversion, therapy has focused on management 
of the arrhythmia’s consequences. Primary among these 
have been ventricular rate control, anticoagulation therapy 
and, where feasible, pharmacologic maintenance of sinus 
rhythm. Pharmacologic therapies have been widely used with 
varying degrees of success. According to the American Heart 
Association, several drugs effectively restore and maintain 
sinus rhythm in patients with AF but usually in the range of 
30-45%. However, to date, little data is available to confirm 
the superiority of one particular drug over another for this 
purpose except for amiodarone, which is associated with 
potentially significant side effects. Agents such as digitalis, 
verapamil, diltiazem, and beta-adrenergic blockers may be 
useful during AF to decrease the ventricular response that 
occurs by inducing atrioventricular (AV) nodal blockade 
but these agents rarely terminate AF.5 The class IC and III 
antiarrhythmic agents have a variable success rate in restoring 
sinus rhythm and new agents are under active investigation. In 
addition, various ablative and surgical techniques have been 
employed to manage AF (also with varying degrees of suc-
cess). These techniques continue to evolve with technologic 
advances facilitating their implementation.
A concomitant condition found in many patients with 
AF commonly requires bradycardia pacing. A considerable 
body of research, both retrospective and prospective, has 
examined the effects of pacing on this arrhythmia. Some 
of the early pertinent research initially focused on the long-
term results of single-chamber ventricular vs. atrial or dual-
chamber pacing. Sasaki6 reported on 103 patients with sick 
sinus syndrome, divided into unpaced, ventricular paced and 
physiologically (atrial or dual chamber) paced groups. The 
VVI group exhibited significantly more complications overall 
than the physiologically paced group with the predominant 
complications being AF in 36% and thromboembolism in 
20%. Stangl7 reported on 222 patients with sick sinus syn-
drome; 110 received AAI pacing, and 112 VVI pacing. The 
incidence of chronic AF was over 3 times higher in the VVI 
group. Feuer8 reported on 220 patients paced for sinus node 
disease and AV block; half were VVI-paced, and half were 
DDD/DDI paced. Again, AF developed more frequently in 
the VVI group. The authors suggested that both preservation 
of AV synchrony and electrical stabilization of the sinus node 
and atrium might account for the apparently protective effect 
of dual-chamber pacing. Reporting on a larger group (950 
patients) of pacemaker recipients followed for up to 8 years, 
Hesselson9 found chronic AF developed significantly more 
frequently in the VVI group than in the DDD and DVI-paced 
patients. These findings were reproduced by Andersen10 who, 
in the first prospective randomized trial comparing AAI to 
VVI, confirmed the apparent protective effect of atrial pacing 
on the subsequent development of AF: cumulative indices of 
both paroxysmal AF and chronic AF were significantly lower 
in the atrially paced group.
As this pattern emerged, investigators examined the 
characteristics of atrial pacing more closely, and overdrive ap-
peared to be the likely mechanism, particularly in the setting of 
an underlying bradycardia. However, even when an underlying 
bradycardia was not present, a beneficial effect of pacing has 
been suggested. Ragonese11 examined a small group of pace-
maker recipients who had surgical repair of complex congenital 
heart disease and atrial reentrant tachycardias unresponsive 
to conventional pharmacologic therapy. Pacemakers were 
specifically programmed to a rate 20% higher than the mean 
intrinsic atrial rate previously determined via Holter record-
ing. A total of 83% of the patients were arrhythmia-free at the 
end of the study. Stabile12 found that atrial pacing markedly 
reduced AF using DDDR pacemakers programmed to a lower 
rate of 75/min, with rate response parameters programmed 
to help assure continuous pacing by having the paced rate 
always faster than the underlying sinus rate. Garrigue13 also 
evaluated atrial overdrive in 22 patients with DDD pacemak-
ers, and found no atrial arrhythmias in 14, and a reduction in 
the number and duration of arrhythmias in the remaining 8 
compared to the baseline studies.
Continuing clinical research and technological evolution 
have produced a variety of device-based technologies in an at-
tempt to control AF. The atrial defibrillator14 has been studied, 
as has multi-site atrial pacing15 and bi-atrial pacing.16 While 
one or more of these newer approaches may prove practical, 
they are problematic at present. Internal atrial defibrillation 
is uncomfortable for patients who are not experiencing a 
life-threatening arrhythmia, while multi-site pacing requires 
significantly more hardware, pulse generator adaptation and 
is far more complex than a standard implant.
By addressing the proposed mechanisms responsible for 
AF (long-short cycles, increased temporal dispersion of re-
fractoriness, frequent atrial ectopic beats), overdrive appears 
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to be a promising technique to postpone or even prevent 
entirely the development of chronic AF while reducing the 
incidence of paroxysmal AF. Sufficiently rapid atrial pacing 
can eliminate the pauses following ectopic beats, overdrive 
and hence suppress atrial ectopy, and reduce the dispersion of 
refractoriness by maintaining control of both rate and rhythm. 
Simply pacing at a relatively fast rate from a single site, as 
demonstrated by Saksena15 may be very effective. However, 
sustained pacing at a high base rate without allowing for the 
normal circadian variation and slowing in the heart rate may 
have adverse hemodynamic consequences as suggested by 
Chew and colleagues.17
The observations regarding the apparently beneficial effect 
of relatively high rate pacing led to the development of a pac-
ing algorithm designed to provide a high percentage of atrial 
pacing just above the patient’s own intrinsic atrial rate, while 
allowing the paced rate to fluctuate in accord with either sen-
sor drive or the patient’s intrinsic atrial rhythm. The goal was 
to maintain the normal circadian variation in the heart rate, 
allow the rate to slow to relatively low levels when the patient 
was at rest, as long as this rate was faster by a programmable 
number of beats than the patient’s intrinsic atrial rhythm. In 
this manner, the algorithm would both overdrive suppress the 
development of paroxysmal AF while avoiding the theoretical 
adverse consequences of a high sustained base rate. The result-
ant algorithm is a dynamic stimulation technique to suppress 
AF effectively, overdrives the atrium just enough to prevent 
the intrinsic rhythm from emerging while maintaining both 
normal diurnal variation and rate response.
D e S C R I P T I O N  O F  A L G O R I T H M
St. Jude Medical designed the Dynamic Atrial Overdrive 
(DAO) algorithm specifically to maintain an atrial stimulation 
rate just above the patient’s intrinsic rate. It accomplishes this 
by continually monitoring the atrial rate, promptly increasing 
the stimulation rate when the intrinsic rhythm emerges defined 
as at least two intrinsic (sensed) P waves. While these sensed 
atrial events do not have to be consecutive, they should occur 
within 16 cycles at which time, the pacing rate is incremented 
in accord with the lower or upper rate overdrive value. As-
suming that there is stable atrial pacing at the higher rate, 
this continues for a programmable number of cycles. Upon 
completion of the overdrive duration criteria, the algorithm 
begins to gradually reduce the stimulation rate to search for 
intrinsic atrial activity thus ensuring that the stimulation rate 
does not persist at an inappropriately rapid level. In essence, 
the DAO algorithm reflects the circadian rhythm while de-
livering a high percentage of atrial pacing at a rate which is 
only slightly above the intrinsic rhythm
The number of beats per minute increase is a program-
mable value from 5 to 25 bpm at lower rates and from 5 to 10 
bpm at higher rates (above 150 bpm). If, despite the initial rate 
increase, the subsequent atrial events continue to be sensed, 
the algorithm continues to increase the rate in similar steps. 
The magnitude of the increase is programmable, with sepa-
rate values (Lower Rate Overdrive or LRO and Upper Rate 
Overdrive or URO) controlling the degree of rate increase. 
Since rate variability is typically greater at lower rates, the 
Lower Rate Overdrive parameter allows a more aggressive 
rate increase than the Upper Rate Overdrive parameter. 
The increased rate is maintained for the selected Number of 
Overdrive Cycles, after which the system begins to search for 
the intrinsic rate by gradually extending the atrial stimulation 
interval. This extension is controlled by the selected DAO Rate 
Recovery parameter, which, like the overdrive parameter, 
has separate components for higher (>100 /min ) and lower 
rate ranges. Each atrial interval is extended by the selected 
millisecond value until two intrinsic atrial events are detected 
within 16 consecutive cycles, at which point the atrial paced 
rate is again increased.
The DAO algorithm is CE marked and incorporated in 
Trilogy® DR/DAO model 2364. It is also incorporated in the 
multichamber Frontier’” model 5510 and 5530 pulse genera-
tors. The DAO parameters and their programmable ranges 
are shown in Table 1.
Although the DAO algorithm requires the continued 
use of the microprocessor integral to the pacemaker, it does 
not limit the behavior of any of the other algorithms. In fact, 
it may augment the behavior of those algorithms. For the 
patient who has an intact sinus mechanism with the expected 
circadian rhythm, the DAO algorithm will track it driving the 
effective paced rate slightly above the sinus rate but with ap-
propriate normal diurnal variation. In the patient with severe 
sinus node dysfunction in addition to the paroxysmal AF, the 
TABLe I.
Parameter values
Recommended 
Settings
Lower Rate Overdrive (LRO) 5, 10, 15,  
20, 25-1
10
Upper Rate Overdrive (URO) 5,10-1 5
Number of Overdrive Pacing 
Cycles*
1 to 16  
in steps of 1
12-16
Dynamic Recovery Rate 
(DRR)**
6:13, 6:19; 
13;19; 19;25 
ms/cycle
6;13
* Preliminary clinical trial data suggests that programming the number 
of overdrive pacing cycles between 12 to 16 provides the best results.
** The first value of the pair specifies the pacing interval extension 
for rates above 100 per minute and the second value specifies the 
milliseconds per cycle extension for rates below 100/min
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rhythm will be predominantly paced in the atrium and diurnal 
variation can still be accomplished using the dynamic sleep 
rate algorithm.18,19
A relatively high base rate is programmed for when the 
patient is active. Any sensor drive associated with physical 
activity starts from this higher base rate. When the patient is 
sleeping or during protracted periods of rest as with an after-
noon nap, the rate is allowed to slow to as low as the sleep rate. 
As there is atrial pacing at all these times, the DAO feature 
of the system would be on standby. However, should there 
be an increase in intrinsic atrial activity, whether it due to 
increased ectopy associated with the lower sleep rate or during 
a period of physical activity with even thought the paced rates 
are higher due to sensor drive, the detected atrial signals will 
cause activation of the DAO algorithm resulting in a further 
increase in the paced rate in accord with the DAO feature.
D e M O N S T R A T I O N  
O F  A L G O R I T H M  B e H A v I O R
While one can monitor the ECG as shown in Figure 1 
to document the behavior of the algorithm, it is elegantly 
demonstrated using the one of the diagnostic event counters 
integral to the pacemaker. This is the Event Record which is a 
time based total system performance counter.20-22 This counter 
can be set to monitor every event in which case it will provide 
an overview of the pacing system behavior for the preceding 
2 hours or it can be set to monitor the system behavior every 
26 seconds at which time it provides an overview covering the 
preceding 60 hours. Once the data pool is filled, the system 
continuously updates the available data by deleting the oldest 
information while adding the newest information concerning 
pacing state and pacing rate with respect to time.
To demonstrate the behavior of the algorithm, the re-
cordings starting with Figure 1 were obtained from a dog 
implanted with a Frontier biventricular pacing system. For the 
purposes of these illustrations, the biventricular stimulation is 
inconsequential. The animal had a marked sinus arrhythmia 
and wide fluctuations of the heart rate are shown. Following 
activation of the algorithm, the degree of fluctuation was 
markedly reduced (Figure 2). In this display, the horizontal 
axis is the time base and is divided into 40 equal segments. If 
there is more than a single event in the time bin, a vertical line 
will be displayed. The top of the vertical line represents the 
peak rate while the bottom represents the minimum rate. The 
crossbar represents the electrical mean rate. The thin vertical 
line extending from top to bottom represents the program-
ming command which, in this case was activation of the DAO 
algorithm. The heavy line in the middle of the printout is a 
centering line provided by the programmer.
The Event Record scale can be expanded to show every 
event. Figure 3 shows the actual transition from DAO off 
to DAO on. Prior to enabling DAO (top), the rhythm was 
atrial sensed [P] ventricular paced [V] and the marker on the 
printout is a P in a black box or inhibited (atrial sensed [P] 
ventricular sensed [R], hence PR represented by an isolated P 
label. There is a considerable excursion in the PV rate associ-
ated with the marked sinus arrhythmia in this animal. After 
a few cycles, the DAO algorithm starts AV pacing identified 
by an A within a box (bottom printout).
Figure 5 was retrieved as the atrial paced rate was decreasing in 
accord with the programmed Dynamic Recovery Rate until na-
tive P waves are again detected and the paced rate increases.
PROSPe C T I v e C L I N ICA L ST U DI e S
To evaluate the clinical effectiveness of this algorithm, two 
prospective randomized multicenter trials have been initiated. 
Titled Atrial Dynamic Overdrive Pacing Trial (ADOPT), they 
have been further labeled A and B.
FIGURe 1. The first three cycles represent AV pacing with a progressive increment in the basic pacing interval consistent with a pro-
gressive slowing of the paced rate. Intrinsic P waves are detected at a slightly higher rate followed by an increase in the atrial paced 
rate. The numeric intervals are paced or sensed AV delay, atrial escape interval and “VV” or the rate interval.
Figure 1 shows an example of the algorithm in operation.
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FIGURe 2. Event Record showing transition between marked sinus arrhythmia with DAO disabled followed by DAO algorithm 
enabled. The arrow identifies the timing of the programming command to enable DAO.
FIGURe 3. Beat-by-beat detail showing development of rate stabilization.
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ADOPT-A involves the subgroup of patients with docu-
mented bradycardia-tachycardia syndrome who would receive 
a pacemaker for symptomatic bradycardias. The comparison 
will be between the incidence of paroxysmal atrial tachyar-
rhythmias, most of which are likely to be AF, with standard 
DDDR pacing at a base rate of 70 ppm and the DAO algorithm 
either enabled or disabled. The number and duration of the 
arrhythmic episodes will be monitored using the Automatic 
Mode Switch Histogram integral to the pacemaker23,24 com-
bined with a transient arrhythmia monitor which each patient 
is given to capture each symptomatic episode. One of these 
recordings was shown in Figure 1.
The entry criterion for ADOPT-B is documented par-
oxysmal atrial tachyarrhythmias continuing to recur despite 
standard pharmacologic regimens in patients who have not 
been identified as having a bradycardia. There will be three 
arms to this trial. In one, the pacemaker will be programmed 
to a base rate of 45 ppm in the DDD mode with both atrial and 
ventricular outputs programmed to 0 volts. The pacemaker 
is functionally inhibited to serve as a control while the DDD 
mode allows the AMS algorithm to remain active so that the 
AMS Histogram can be used as a monitoring system for the 
frequency of spontaneous episodes of atrial fibrillation. In a 
second arm, the pacing mode will be DDD (sensor passive) 
at a base rate of 70 ppm while in the third arm, the mode will 
be DDD (sensor passive), the base rate 70 ppm and DAO will 
be enabled.
Neither of these trials has completed enrollment and 
FIGURe 4. Represents the expected fluctuation in rate in the midst of the DAO algorithm. There are a few intrinsic sensed atrial 
events (P) at which point there is an increase in the atrial paced rate.
FIGURe 5. Alter a period of stable atrial pacing, the rate is progressively decreased (interval between consecutive beats is increased) 
until native atrial activity is again sensed as identified by the P marker. With detection of two P waves, the paced atrial rate is in-
creased in accord with the programmed overdrive steps. If P waves are still detected, the rate is again increased until atrial pacing 
occurs.
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episodes lasted for significant although shorter periods of 
time. In the 3-month period following enabling of the DAO 
algorithm, there was a marked reduction in mode switch 
episodes, all other parameters in the pacemaker including 
the pharmacologic regimen being stable. There were only 5 
mode switch episodes with no episode lasting more than 6 
minutes (Figure 6B).
S U M M A R y
Dynamic Atrial Overdrive is a unique pacemaker algo-
rithm designed specifically for suppression of paroxysmal 
supraventricular tachycardias, most of which will be AF arising 
from either an absolute or relative bradycardia. In this case, 
relative refers to a heart rate that is slower than physiologically 
optimal even if it is rapid. By maintaining an atrial stimulation 
rate just above the intrinsic rate, the goal is to control both the 
atrial rate and rhythm, reducing the incidence of ectopic beats 
which might be a trigger, long-short cycles, or the dispersion of 
the cumulative data has not yet been analyzed and as such, 
cannot be reported at this time. Of the data that has been 
submitted, some patients have had a dramatic response to 
the DAO algorithm.
C A S e  S T U D y
The patient is an 80 year-old man with bradycardia-tachy-
cardia syndrome and frequent episodes of paroxysmal AF. 
Previous pharmacologic therapy to control the AF included 
a Class IC agent (propafenone) which was ineffective in 
stabilizing the atrium yet exacerbated the underlying sinus 
bradycardia. As such, the propafenone was discontinued and 
a DDDR pacemaker (Trilogy DR/DAO) was implanted. The 
patient was initially randomized to standard DDDR pacing. 
Despite standard pacing techniques, he continued to have 
frequent symptomatic episodes of paroxysmal AF with 6,240 
mode switch episodes during this time interval (Figure 6A). 
One episode lasted between 15 to 30 hours and multiple other 
FIGURe 6A. AMS Histogram recorded at the end of a 3-month period with the pacemaker programmed to the DDDR mode but the 
DAO algorithm was disabled. There were 6.240 AMS episodes with 98% occurring at a filtered atrial rate above 300 bpm consistent 
with the patient’s known paroxysmal AF.
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